Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
{{output}}
The Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is one of the most prevalent activating alterations in cancer. It indicates a poor overall prognosis due to its highly invasive nature. Although several KRAS inhibitors have been developed in recen... ...
